Pandion bags $58M; Carmot Therapeutics grabs $15M; Innovent looks for IPO; Collaboration of Sandoz & Biocon

Pandion Therapeutics bags USD 58 million in series A Funding

Focused on developing Targeted immune modulator drugs, Pandion Therapeutics has successfully grabbed USD 58 million in series A funding. The company is led by highly experienced professionals. Anthony Coyle (former senior vice president at Pfizer and global head of biologics at MedImmune) has signed on as CEO and Jo Viney (former head drug discovery and immunology research at Biogen) joined as the Chief scientific officer.

Carmot Therapeutics grabs USD 15 million for GLP-1R/GIPR agonist

In a recent funding, Carmot Therapeutics has successfully grabbed USD 15 million in series B, the company will further carry its lead Type 2 diabetes drug, a GLP-1R/GIPR agonist, through clinical trials. The funding will further help the company in several preclinical trials in the area of Obesity, diabetes, and fatty liver disease.

Chinese pharma company Innovent Biologics is looking for IPO this year

Chinese pharma company Innovent Biologics is considering a USD 200 million IPO later this year possible in the U.S. According to an article recently published in the Bloomberg, Shanghai-based pharma company Innovent is on the verge of another investment round ahead of the IPO that could possibly involve U.S. asset manager Capital Group. Innovent is also considering listing in Hong Kong.

Global biosimilars leader Sandoz has recently announced exclusive global collaboration with Biocon on next-generation biosimilars

Sandoz is a global leader in biosimilars and a division of pharma giant Novartis. It has recently announced a global partnership with Asia’s premier biopharmaceuticals company, Biocon. Collaboration is aimed to develop, manufacture and commercialize multiple biosimilars in the area of immunology and oncology for patients worldwide.